Theravance SVP granted 37,500 TBPH shares

Grimaud Brett A. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Grimaud Brett A. reported acquisition or exercise transactions in this Form 4 filing.

Theravance Biopharma, Inc. executive Brett A. Grimaud, SVP, General Counsel and Secretary, received a grant of 37,500 Ordinary Shares on April 1, 2026. The shares were awarded at a stated price of $0.00 per share as compensation rather than a market purchase. Following this grant, his direct holdings increased to 371,949 Ordinary Shares, according to the filing.

Insights

Equity compensation analyst

Routine equity grant increases insider’s holdings without open‑market buying.

The filing shows Theravance Biopharma’s SVP and General Counsel received 37,500 Ordinary Shares as a share grant at $0.00 per share. This is a compensation-related award, not an open-market transaction, and therefore carries weaker signaling value than a discretionary share purchase.

After the grant, his direct holdings total 371,949 Ordinary Shares. With no derivative positions disclosed and no sales in this filing, the overall picture is an increase in equity exposure through standard executive compensation rather than a change driven by market trading decisions.

Insider Trade Summary

Grant/Award: 37,500 shares

Grant/Award 1 txn

Insider Grimaud Brett A.

Role SVP, GEN COUNSEL AND SECRETARY

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	37,500	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 371,949 shares (Direct)

Key Figures

Share grant size: 37,500 shares Grant price per share: $0.00 per share Shares held after transaction: 371,949 shares +1 more

4 metrics

Share grant size 37,500 shares Ordinary Shares granted on April 1, 2026

Grant price per share $0.00 per share Stated transaction price for awarded Ordinary Shares

Shares held after transaction 371,949 shares Total direct Ordinary Share holdings after the grant

Number of acquire transactions 1 transaction Single grant/award acquisition in this Form 4

Key Terms

Ordinary Shares, Grant, award, or other acquisition, Form 4

3 terms

Ordinary Shares financial

"security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Theravance Biopharma (TBPH) report for Brett A. Grimaud?

Theravance Biopharma reported that SVP and General Counsel Brett A. Grimaud received a grant of 37,500 Ordinary Shares. The award was recorded at a price of $0.00 per share, indicating a compensation-related share grant rather than an open-market purchase or sale.

How many Theravance Biopharma (TBPH) shares does Brett A. Grimaud hold after this Form 4?

After the reported transaction, Brett A. Grimaud directly holds 371,949 Ordinary Shares of Theravance Biopharma. This total reflects the addition of 37,500 granted shares on April 1, 2026, as disclosed in the Form 4 insider filing data.

Was the Theravance Biopharma (TBPH) insider transaction a buy or a grant?

The transaction was classified as a grant or award acquisition, not an open-market buy. The Form 4 uses code “A” with the description “Grant, award, or other acquisition,” and shows 37,500 Ordinary Shares at a transaction price of $0.00 per share.

Did Brett A. Grimaud sell any Theravance Biopharma (TBPH) shares in this Form 4?

No sales were reported in this Form 4. The insider filing shows only an acquisition of 37,500 Ordinary Shares via a grant, with zero transactions marked as sells and no disposition-related transaction codes in the summary data.

What does transaction code "A" mean in the Theravance Biopharma (TBPH) Form 4?

Transaction code “A” in this Form 4 stands for a grant, award, or other acquisition of securities. In Brett A. Grimaud’s case, it indicates that 37,500 Ordinary Shares were granted at a stated price of $0.00 per share as part of equity compensation.

Does the Theravance Biopharma (TBPH) Form 4 show any options or derivatives for Brett A. Grimaud?

The derivative summary in the filing is empty, indicating no derivative security transactions were reported in this Form 4. Only a non-derivative grant of 37,500 Ordinary Shares and the resulting total of 371,949 Ordinary Shares are disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 06:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grimaud Brett A.

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GEN COUNSEL AND SECRETARY

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/01/2026		A		37,500	A	$0	371,949	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Brett A Grimaud	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)